We are live on
!
Find out more
DMPV
Delphi Management Partners VIII Portfolio holdings
AUM
$138M
1-Year Est. Return
56.74%
This Fund
S&P 500
This Quarter
Est. Return
+2.1%
1 Year Est. Return
+56.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
–
Cap. Flow
+$154M
Cap. Flow
% of AUM
100.95%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$103M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$35M |
| 3 |
CALA
Calithera Biosciences, Inc
CALA
|
+$10.6M |
| 4 |
Senseonics Holdings Inc
SENS
|
+$4.29M |
| 5 |
MREO
Mereo BioPharma
MREO
|
+$643K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.17% |
Similar funds
HC
FIG
BRC
RP
CSM
SVC
SCM
KGA
Delphi Management Partners VIII's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Delphi Management Partners VIII, which disclosed 5 positions worth $152M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Tandem Diabetes Care: 1,000,000 shares worth $95.7M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets.
- Delphi Management Partners VIII's largest Q4 2020 buy was Tandem Diabetes Care: 1,000,000 shares worth $95.7M.
- Delphi Management Partners VIII's ten largest holdings make up 100% of its $152M portfolio in Q4 2020.
- Delphi Management Partners VIII disclosed 5 positions in Q4 2020, its first 13F filing on record.
Based on Delphi Management Partners VIII's 13F filing for Q4 2020, filed 8 Feb 2021.